5-fluorouracil pharmacokinetics: causes for variability and strategies for modulation in cancer chemotherapy

Cancer Invest. 1999;17(7):494-506. doi: 10.3109/07357909909032859.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Administration, Oral
  • Animals
  • Antimetabolites, Antineoplastic / administration & dosage
  • Antimetabolites, Antineoplastic / pharmacokinetics*
  • Dihydrouracil Dehydrogenase (NADP)
  • Drug Administration Schedule
  • Fluorouracil / administration & dosage
  • Fluorouracil / antagonists & inhibitors
  • Fluorouracil / pharmacokinetics*
  • Humans
  • Infusions, Intravenous
  • Oxidoreductases / antagonists & inhibitors
  • Oxidoreductases / genetics
  • Prodrugs / administration & dosage
  • Prodrugs / pharmacokinetics

Substances

  • Antimetabolites, Antineoplastic
  • Prodrugs
  • Oxidoreductases
  • Dihydrouracil Dehydrogenase (NADP)
  • Fluorouracil